The Life Sciences Report: Given the ups and downs in the stock markets, what is the best capital-seeking strategy for a life science company?
Pooya Hemami: It all comes down to smart risk management and the practicalities of internal fund allocation. Biotechs should focus research and development spending on the most advanced assets in their product pipelines, the items that can more quickly reach value-enhancing milestones and attract partnerships.
Some firms make the mistake of spending resources on multiple projects and, consequently, they find themselves with a … [visit site to read more]
Similar posts:- Porter Stansberry Reveals the Greatest Threat to the U.S. Economy and One Easy Way to Protect Yourself The Gold Report: When we spoke in December, you said...
- How to Stress Test Gold Equities: Joe Mazumdar The Gold Report: Where can long-term gold investors look for...
- Alka Singh: Is a False Perception of Risk Pummeling Your Profits? The Gold Report: Alka, gold is off to a weak...
